<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00075621</url>
  </required_header>
  <id_info>
    <org_study_id>H-23645</org_study_id>
    <nct_id>NCT00075621</nct_id>
  </id_info>
  <brief_title>Tandem Autologous Stem Cell Transplantation in Treating Patients With Primary Systemic (AL) Amyloidosis</brief_title>
  <official_title>A Phase II Trial of Tandem Transplantation in AL Amyloidosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boston Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boston Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Autologous stem cell transplantation may be effective treatment for primary
      systemic (AL) amyloidosis.

      PURPOSE: This phase II trial is studying how well tandem (two) autologous stem cell
      transplantation works in treating patients with primary systemic (AL) amyloidosis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

        -  Determine the tolerability of tandem autologous stem cell transplantation in patients
           with AL amyloidosis.

        -  Determine whether this regimen can convert a hematologic non-complete response (CR) to
           CR in these patients.

        -  Determine the overall survival of patients treated with this regimen.

      OUTLINE:

        -  First transplantation: Patients receive filgrastim (G-CSF) subcutaneously once daily
           beginning 3 days before the initiation of stem cell collection and continuing until the
           day before the completion of stem cell collection. Patients may undergo bone marrow
           harvest if an inadequate number of peripheral blood stem cells are collected.

      Patients receive high-dose melphalan IV over 20 minutes on days -3 and -2. Patients undergo
      autologous stem cell transplantation (ASCT) on day 0.

        -  Second transplantation: Within 6-12 months after the first ASCT, patients not achieving
           a complete response receive high-dose melphalan IV over 20 minutes on days -3 and -2 and
           a second ASCT on day 0.

      Treatment continues in the absence of unacceptable toxicity.

      Patients are followed at 3 and 6 months, 1 year, and then annually thereafter.

      PROJECTED ACCRUAL: A total of 62 patients will be accrued for this study within 2-3 years.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>August 2000</start_date>
  <completion_date type="Anticipated">May 2018</completion_date>
  <primary_completion_date type="Actual">June 2005</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>safety</measure>
    <time_frame>100 days, 6 months, and annual</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy</measure>
    <time_frame>one year</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">62</enrollment>
  <condition>Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>tandem transplant</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Drug: filgrastim 16 mg/kg/day for 3 days prior to stem cell collection, through day before last collection
Drug: melphalan 200 mg/kg over 2 days
Procedure/Surgery: autologous peripheral blood stem cell transplantation
autologous peripheral blood stem cell transplantation</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>filgrastim</intervention_name>
    <description>16 mg/kg/day for 3 days prior to stem cell collection, through day before last collection</description>
    <arm_group_label>tandem transplant</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>melphalan</intervention_name>
    <description>200 mg/kg over 2 days</description>
    <arm_group_label>tandem transplant</arm_group_label>
    <other_name>alkeran</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>autologous peripheral blood stem cell transplantation</intervention_name>
    <description>autologous peripheral blood stem cell transplantation</description>
    <arm_group_label>tandem transplant</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        DISEASE CHARACTERISTICS:

          -  Histologically confirmed AL amyloidosis, meeting 1 of the following criteria:

               -  Plasma cell dyscrasia, evidenced by 1 of the following:

                    -  Monoclonal protein in the serum or urine by immunofixation electrophoresis

                    -  Plasmacytosis of the bone marrow with monoclonal staining for kappa or
                       lambda light chain isotype

               -  Macroglossia with at least 1 other site having biopsy proven amyloidosis and
                  absence of a mutant transthyretin is ruled out

        PATIENT CHARACTERISTICS:

        Age

          -  18 to 65

        Performance status

          -  SWOG 0-2

        Life expectancy

          -  At least 1 year

        Hematopoietic

          -  Not specified

        Hepatic

          -  Not specified

        Renal

          -  Not specified

        Cardiovascular

          -  LVEF ≥ 45% by MUGA or echocardiogram

        Pulmonary

          -  DLCO ≥ 50%

        Other

          -  Not pregnant or nursing

          -  Fertile patients must use effective contraception

          -  Able to tolerate 2 courses of high-dose therapy

          -  HIV negative

        PRIOR CONCURRENT THERAPY:

        Biologic therapy

          -  Not specified

        Chemotherapy

          -  Prior alkylating agent chemotherapy allowed provided there is no morphologic or
             cytogenetic evidence of myelodysplastic syndromes

          -  Prior total cumulative oral melphalan dose &lt; 300 mg

        Endocrine therapy

          -  Not specified

        Radiotherapy

          -  Not specified

        Surgery

          -  Not specified

        Other

          -  At least 4 weeks since prior cytotoxic therapy and recovered

        Exclusion Criteria:

          -  No senile, secondary, localized, dialysis-related, or familial amyloidosis

          -  No overt multiple myeloma (e.g., greater than 30% bone marrow plasmacytosis, extensive
             [more than 2] lytic lesions, hypercalcemia)

        Cardiovascular

          -  No myocardial infarction within the past 6 months

          -  No congestive heart failure

          -  No arrhythmia refractory to therapy

          -  No evidence of symptomatic transient ischemic attacks or strokes

          -  No other malignancy within the past 5 years except adequately treated basal cell or
             squamous cell skin cancer, carcinoma in situ of the cervix, or adequately treated
             stage I or II cancer currently in complete remission
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vaishali Sanchorawala, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Boston Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cancer Research Center at Boston Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02118</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 9, 2004</study_first_submitted>
  <study_first_submitted_qc>January 11, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 12, 2004</study_first_posted>
  <last_update_submitted>April 9, 2018</last_update_submitted>
  <last_update_submitted_qc>April 9, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 11, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Boston Medical Center</investigator_affiliation>
    <investigator_full_name>Vaishali Sanchorawala</investigator_full_name>
    <investigator_title>BMC Faculty</investigator_title>
  </responsible_party>
  <keyword>primary systemic amyloidosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Amyloidosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melphalan</mesh_term>
    <mesh_term>Lenograstim</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

